These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23383527)

  • 1. [Psoriasis induced by a TNF-alpha antagonist in a patient with ulcerative colitis].
    Machado RI; Souto LM; Freire EA
    Acta Gastroenterol Latinoam; 2012 Dec; 42(4):325-8. PubMed ID: 23383527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
    Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
    An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
    Baglieri F; Scuderi G
    Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
    Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
    Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases.
    Sun G; Wasko CA; Hsu S
    J Drugs Dermatol; 2008 Jan; 7(1):69-71. PubMed ID: 18246701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients.
    Severs GA; Lawlor TH; Purcell SM; Adler DJ; Thompson R
    Cutis; 2007 Sep; 80(3):231-7. PubMed ID: 17956013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-α antagonists: Side effects and their management.
    Dogra S; Khullar G
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S35-46. PubMed ID: 23974693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pustular psoriasis induced by infliximab.
    Thurber M; Feasel A; Stroehlein J; Hymes SR
    J Drugs Dermatol; 2004; 3(4):439-40. PubMed ID: 15303790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.